Medical Oxygen Systems Market (2026-2036)

The growth of this market is mainly driven by rising global commitment to closing the medical oxygen coverage gap, increasing policy obligation under World Health Assembly resolution WHA76.3, the growing burden of chronic respiratory disease and childhood pneumonia, increasing adoption of high-flow nasal oxygen in hospital care, and expanding home and long-term oxygen therapy provision. However, the normalisation of equipment demand after pandemic-era procurement, bundled reimbursement and the thirty-six month payment cap in home oxygen, electricity supply reliability and tariff exposure in on-site generation, and the high capital cost of pipeline compliance in existing buildings restrain the growth of this market.

Furthermore, donor-funded and multilateral oxygen investment through 2030, expanding regional liquid oxygen production capacity in Africa, growing demand for managed oxygen and oxygen-as-a-service contracting, and the rising deployment of off-grid and solar-powered oxygen generation are expected to offer growth opportunities for the stakeholders in this market. However, sustaining the functionality of installed generation capacity, shortages of biomedical engineering and certified verification capacity, pharmacopoeial and quality compliance for on-site generated oxygen, cylinder logistics and point-of-use safety, and the concentration of oxygen funding among a small number of institutions remain major challenges impacting the growth of this market. Additionally, the growing acceptance of oxygen 93 percent as a pipeline-grade product, rising standardisation across refreshed oxygen equipment standards, increasing deployment of pipeline telemetry and predictive maintenance, growing consolidation of oxygen delivery consumable supply, and the expansion of local manufacturing of oxygen equipment and gas supply in Africa and Asia are prominent trends in this market.

The Medical Oxygen Systems Market comprises the equipment, systems and attached services through which medical oxygen is generated, stored, distributed and delivered to patients across hospital, pre-hospital and home care settings. The market includes oxygen source and generation systems covering pressure swing adsorption and vacuum pressure swing adsorption plants, stationary and portable oxygen concentrators, cryogenic bulk storage tanks, vacuum-insulated evaporators and high-pressure cylinder and automatic changeover manifold systems; medical gas pipeline and distribution systems covering degreased medical copper pipework, area valve service units, terminal units, line pressure regulators, flowmeters, oxygen blenders and master and area alarm panels; oxygen therapy delivery devices and consumables covering nasal cannulae, simple, venturi and non-rebreather masks, high-flow nasal oxygen systems, heated humidifiers and breathing circuits, oxygen conserving devices and supply tubing; and the installation, verification, maintenance and home oxygen services attached to this equipment. Mechanical ventilators, anaesthesia delivery systems, hyperbaric chambers, medical air, vacuum and nitrous oxide systems, and the sale of the oxygen molecule itself as bulk liquid or cylinder fill are excluded. The market ecosystem extends from zeolite, compressor and cryogenic component suppliers to plant, concentrator, cylinder and pipeline equipment manufacturers, industrial gas groups, certified installers and verifiers, home medical equipment providers, and the hospitals, emergency services, health ministries and patients that commission and use these systems.

The market is experiencing steady growth as medical oxygen moves from an emergency response commodity to a funded component of health infrastructure. The Lancet Global Health Commission on medical oxygen security, published on 17 February 2025, found that more than 5 billion people, over 60% of the world population, lack access to safe, quality and affordable medical oxygen services, that approximately 374 million people require medical oxygen each year with 82% of them in low- and middle-income countries, and that of 299.3 million people with acute medical or surgical need in those countries only 89.3 million receive it. The Commission measured coverage of acute medical need at 9% across sub-Saharan Africa, 22% in South Asia and 26% in East Asia and the Pacific, and put the cost of closing these gaps at USD 6.8 billion a year, or USD 34.0 billion across 2025 to 2030. Increasing investments in generation plants, cryogenic storage, pipeline infrastructure, concentrators and delivery devices are significantly increasing demand across the market.

Clinical demand is further strengthening market growth, as the conditions that require oxygen remain among the largest causes of death worldwide. The World Health Organization records approximately 3.4 million deaths from chronic obstructive pulmonary disease in 2023, around 6% of all deaths globally and the third leading cause of death, with nearly 90% of deaths in people under 70 occurring in low- and middle-income countries, while 740,180 children under five died of pneumonia in 2019, equal to 14% of all deaths in that age group. The therapies used to treat these patients are also raising the flow each bed must receive, with design figures cited by the Healthcare Safety Investigation Branch placing mechanical ventilators at approximately 15 litres per minute and continuous positive airway pressure at approximately 30 litres per minute against more than 60 litres per minute for high-flow nasal oxygen. Fisher & Paykel Healthcare, which supplies the leading high-flow platform, reported Hospital revenue of NZD 1.51 billion for the year ended 31 March 2026, up 18%, within operating revenue of NZD 2.31 billion.

Demand across low- and middle-income countries is being reshaped by the legacy of pandemic-era procurement and by the cost of sustaining it. The ACT-Accelerator Oxygen Emergency Taskforce mobilised more than USD 1 billion between 2021 and 2023 and delivered 879 pressure swing adsorption plants, 1,019 liquid oxygen tanks, 26,000 cylinders, approximately 225,920 oxygen concentrators and 350,262 pulse oximeters across around 120 countries, while training more than 74,000 health workers and biomedical engineers. Keeping that base in service has proved harder than installing it. The Nigerian national assessment conducted between June and September 2022 across 6,786 facilities found 30 of 39 identified pressure swing adsorption plants functional, 24% of 5,741 oxygen concentrators non-functional and 23% of 8,824 pulse oximeters non-functional, and the Lancet Commission found that oxygen stockouts or interruptions affect 93% of primary care facilities, 45% of general hospitals and 25% of tertiary hospitals. The Global Oxygen Alliance accordingly places the baseline cost of maintaining and operating existing systems at approximately USD 8.2 billion.

Another major growth driver is the change in standards that places on-site generation on the same footing as delivered cryogenic oxygen. The fourth edition of ISO 7396-1 entered the under-publication stage on 23 September 2026 and applies both where all sources deliver oxygen above 99% and where all sources deliver oxygen 93 at a concentration between 90% and 96%, superseding the position in which ISO 10083 governed concentrator supply to pipelines separately before its withdrawal on 15 February 2016. The European Pharmacopoeia monographs specify the product for Oxygen at a minimum of 99.5%, Oxygen 93 per cent and Oxygen 98 per cent, the last adopted at the 176th session of the European Pharmacopoeia Commission in June 2023, and by the United States Pharmacopeia monograph for Oxygen 93 Percent requiring 90.0% to 96.0% oxygen by volume. World Health Organization technical specifications for pressure swing adsorption plants describe production of oxygen 93% plus or minus 3% from ambient air, and the essential medicines listing estimates oxygen cost at USD 2 to USD 8 per 1,000 litres from concentrators against USD 10 to USD 30 per 1,000 litres from cylinders.

Demand in high-income markets is increasingly being met through home oxygen provision and service contracting rather than through capital equipment purchase. Air Liquide reported Healthcare sales of EUR 4.4 billion in 2025, of which 54% came from Home Healthcare and 37% from medical gases, medical equipment and services, supporting 2.3 million patients at home and serving 20,000 hospitals and clinics across more than 30 countries. SOL Group reported Home Care division revenue of EUR 923.1 million for 2025, up 12.3%, which overtook its Technical Gases division at EUR 852.9 million. Reimbursement constrains realised revenue, as Medicare pays oxygen as a single bundled monthly amount covering equipment, contents and accessories and ends equipment payment after 36 months of continuous use, with competitive bidding paused since 2021 and fee schedule rates updated by the consumer price index, projected at 2.8% for 2026. Inogen reported 2025 revenue of USD 348.7 million with United States sales down 3.1% against international sales up 18.4%.

At the same time, the growing use of telemetry, managed service contracting and regional manufacturing is reshaping the medical oxygen ecosystem and creating new opportunities for suppliers. The Healthcare Safety Investigation Branch found that demand at its reference trust never exceeded 56% of total oxygen supply capacity while high-dependency unit pressure fell from 4.2 bar to 3.1 bar in approximately 10 seconds, establishing distribution rather than supply volume as the principal design question and prompting installation of pipeline flow meters and telemetry. The 2026 edition of Health Technical Memorandum 02-01, reissued in August 2026, adds a technical file requirement, board-level reporting through a Medical Gas Safety Group and new chapters on decommissioning and quality control testing. In parallel, Unitaid committed USD 22 million in October 2024 to four liquid oxygen air separation plants in Kenya and Tanzania expected to add more than 60 tons per day and lower regional prices by up to 27%, working with local manufacturers Hewatele, Synergy and TOL Gases.